Skip to main content

H.R. 1518

Referred to Committee

New Era of Preventing End-Stage Kidney Disease Act

Introduced 2/24/2025•119th Congress•House

Latest Action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2/24/2025 • House

Summary

New Era of Preventing End-Stage Kidney Disease Act

This bill establishes regional centers of excellence, postgraduate fellowships, and training for health professionals relating to the diagnosis and treatment of rare kidney disease. It also requires the Department of Health and Human Services (HHS) to conduct various studies on rare kidney disease.

Specifically, it authorizes the National Institute of Diabetes and Digestive and Kidney Diseases to award funding to public and private nonprofit entities for establishing regional centers of excellence that will increase public awareness, conduct research, and develop resources for diagnosing and treating rare kidney diseases. A center may receive such funding for up to five years, unless extended by the institute. 

The bill also requires health professions schools receiving a grant from the Health Resources and Services Administration (HRSA) Centers of Excellence program to award fellowships for training on preventing, diagnosing, and treating rare kidney disease in disproportionately impacted populations.

Also, the bill expands the priorities of HRSA’s Primary Care Training and Enhancement program to include training for health care workers to care for individuals with kidney disease.

Additionally, HHS must conduct several studies and report to Congress on topics such as treating rare kidney disease in disproportionately affected populations, eliminating the need for dialysis or kidney transplants, and increasing public awareness of rare kidney disease.

Introduced in House • 2/24/2025

Enter your district to see how this bill affects your community
-

Topics & Subjects

Policy Area: Health
Congressional oversightDigestive and metabolic diseasesGeneticsGovernment studies and investigationsHealth care coverage and accessHealth programs administration and fundingHealth promotion and preventive careMedical educationMedical researchMedical tests and diagnostic methodsResearch administration and funding

Congressional Votes (0)

No recorded votes yet

Roll call votes will appear here as the bill moves through Congress

Related Federal Spending

Sponsor & Cosponsors (63)

Party Breakdown

44
Democrats
19
Republicans
0
Independents

Sponsor

R[
Rep. Bilirakis, Gus M. [R-FL-12]

Republican • FL-12

Sponsored 2/24/2025

Cosponsors (62)

R[
Rep. Sewell, Terri A. [D-AL-7]

D-AL-7

Joined 2/24/2025

R[
Rep. Miller, Carol D. [R-WV-1]

R-WV-1

Joined 2/24/2025

R[
Rep. Peters, Scott H. [D-CA-50]

D-CA-50

Joined 2/24/2025

R[
Rep. Balderson, Troy [R-OH-12]

R-OH-12

Joined 2/24/2025

R[
Rep. Tonko, Paul [D-NY-20]

D-NY-20

Joined 2/24/2025

Bill Journey

Originated in the House

Introduced

February 24, 2025

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committee Review

Floor Debate

Passed Chamber

Other Chamber

President

Enacted into Law

Text Versions (1)

Introduced in House2/24/2025

Details

Bill TypeHR
Current StatusReferred to Committee
Cosponsors62